Travere Therapeutics Provides Revenue Guidance for the Fourth Quarter and Full Year of Fiscal 2021
For the fiscal year 2021, the Company expects total revenue of $227 million, inclusive of approximately $211 million in net product sales and approximately $16 million in licensing and collaboration revenue.